ADVANCES IN TUMOR MARKERS FOR THE EARLY DIAGNOSIS OF PAPILLARY THYROID CARCINOMA
DOI:
https://doi.org/10.22159/ijpps.2016v8s2.15221Keywords:
Papillary thyroid carcinoma, Tumor markers, Galectin-3, Ki67, HBME-1, CK19, VEGF-C, Claudin-1Abstract
Papillary Thyroid Carcinoma (PTC) is a common endocrine malignancy and mostly is found in women. Different pathological types of PTC have different biological behaviors. The hidden onset results in difficulties to diagnose the early PTC. With the development of the molecular biology, increasing the number of researchers is a focus on tumor markers. The sensitivity and specificity of these tumor markers are helpful for early diagnosis and therapy of PTC. This review is oriented towards the finding of the potent thyroid cancer markers have enhanced sensitivity and specificity, with diagnostic, prognostic and therapeutic efficiency.
Downloads
References
Kigbu JH，Nyango DD. A critical look on condoms． Niger J Med 2009;18:354-9．
Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030：the unexpected burden of the thyroid, liver, and pancreas cancers in the United States. Cancer Res 2014;74:2913-21．
Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 2009;27:2758–65.
Edwards BK, Noone AM, Mariotto AB, Simard EP, Boscoe FP, Henley SJ, et al. Annual report to the nation on the status of cancer, 1975–2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer 2014;120:1290-314.
Sipos JA, Mazzaferri EL. Thyroid cancer epidemiology and prognostic variables. Clin Oncol 2010;22:395-404．
Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin 2015;65:5-29.
Kim S, Schiff BA, Yigitbasi OG, Doan D, Jasser SA, Bekele BN, et al. Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788. Mol Cancer Ther 2005;4:632–40.
Edafe O，Wadsley J，Harrison BJ，Balasubramanian SP. Treatment-related morbidity in differentiated thyroid cancer-a survey of clinicians. Thyroid Res 2014;7:3．
Peng XG, Chen ZF, Zhang KJ, Wang PG, Liu ZM, Chen ZJ, et al. VEGF trapon inhibits tumor growth in papillary thyroid carcinoma. Eur Rev Med Pharmacol Sci 2015;19:235-40.
Hamzany Y, Soudry E, Strenov Y, Lipschitz N, Segal K, Hadar T, et al. Early death from papillary thyroid carcinoma. Am J Otolaryngol 2012;33:104-8.
Prasad ML, Huang Y, Pellegata NS, de la Chapelle A, Kloos RT. Hashimoto’s thyroiditis with papillary thyroid carcinoma (PTC)-like nuclear alterations expresses molecular markers of PTC. Histopathology 2004;45:39-46.
Murphy KM, Chen F, Clark DP. Identification of immunohistochemical biomarkers for papillary thyroid carcinoma using gene expression profiling. Hum Pathol 2008;39:420-6.
Bartolazzi A, Orlandi F, Saggiorato E, Volante M, Arecco F, Rossetto R, et al. Galectin-3 expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. Lancet Oncol 2008;9:543-9.
Papale F, Cafiero G, Grimaldi A, Marino G, Rosso F, Mian C, et al. Galectin-3 expression in thyroid fine needle cytology (t-FNAC) uncertain cases: validation of molecular markers and technology innovation. J Cell Physiol 2013;228:968-74.
Xue G, Liu J, Huang J, Zhang J, Zhang W, Wu J, et al. Detection of galectin-3 in both serum and tissue for early diagnosis of thyroid carcinoma. Nanfang Yike Daxue Xuebao 2013;33:1027-30.
Song Q, Wang D, Lou Y, Li C, Fang C, He X, et al. Diagnostic significance of CK19, TG, Ki67 galectin-3 expression for papillary thyroid carcinoma in the northeastern region of China. Diagn Pathol 2011;6:126.
Lee YS, Ha SA, Kim HJ, Shin SM, Kim HK, Kim S, et al. Minichromosome maintenance protein 3 is a candidate proliferation marker in papillary thyroid carcinoma. Exp Mol Pathol 2010;88:138-42.
Liu Z, Yu P, Xiong Y, Zeng W, Li X, Maiaiti Y, et al. Significance of CK19, TPO, and HBME-1 expression for diagnosis of papillary thyroid carcinoma. Int J Clin Exp Med 2015;8:4369-74.
de Matos LL, Del Giglio AB, Matsubayashi CO, de Lima Farah M, Del Giglio A, da Silva Pinhal MA. Expression of CK-19, galectin-3, and HBME-1 in the differentiation of thyroid lesions: a systematic review and diagnostic meta-analysis. Diagn Pathol 2012;7:97.
Dencic TM, Savin SB, Selemetjev SA, Paskas SD, Zivaljevic VR, Bozic VD, et al. a Strong expression of HBME-1 associates with high-risk clinicopathological factors of papillary thyroid carcinoma. Pathol Oncol Res 2015;21:735-42.
Ma H, Xu S, Yan J, Zhang C, Qin S, Wang X, et al. The value of tumor markers in the diagnosis of papillary thyroid carcinoma alone and in combination. Pol J Pathol 2014;65:202-9.
Isic Dencic T, Cvejic D, Paunovic I, Tatic S, Havelka M, Savin S. Cytokeratin19 expression discriminates papillary thyroid carcinoma from other thyroid lesions and predicts its aggressive behavior. Med Oncol 2013;30:362.
Bose D, Das RN, Chatterjee U, Banerjee U. Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma. Indian J Med Paediatr Oncol 2012;33:107-11.
Kaczka K, Fendler W, Borowiec M, MÅ‚ynarski W, Celnik A, Pomorski L. Lymph node metastases in papillary thyroid cancer detected by quantitative real-time polymerase chain reaction for thyroglobulin and cytokeratine19. Pol J Pathol 2013;64:90-5.
Laco J, Ryska A, Cáp J, Celakovský P. Expression of galectin-3, cytokeratin 19, neural cell adhesion molecule and E-cadhedrin in certain variants of papillary thyroid carcinoma. Cesk Patol 2008;44:103-7.
Wu G, Wang J, Zhou Z, Li T, Tang F. Combined staining for immunohistochemical markers in the diagnosis of papillary thyroid carcinoma: improvement in the sensitivity or specificity? J Int Med Res 2013;41:975-83.
YeÅŸil C, Kandemir O, Haksever H, DabakoÄŸlu T. Is BECLIN-1 immunoreactivity more effective than HBME-1 in the diagnosis of papillary thyroid cancer? Acta Chir Belg 2015;115:299-305.
Barresi V, Leni A, Tuccari G, Barresi G. Neutrophil gelatinase associated lipocalin (NGAL) immunohistochemical expression in follicular cell-derived thyroid tumors: a novel diagnostic tool? Histol Histopathol 2012;27:329-36.
Ma H, Yan J, Zhang C, Qin S, Qin L, Liu L, et al. Expression of papillary thyroid carcinoma associated molecular markers and their significance in follicular epithelial dysplasia with papillary thyroid carcinoma-like nuclear alterations in Hashimoto's thyroiditis. Int J Clin Exp Pathol 2014;7:7999-8007.
Do SI, Kim DH, Yang JH, Pyo JS, Kim K, Lee H, et al. Decreased expression of p27 is associated with malignant transformation and extrathyroidal extension in papillary thyroid carcinoma. Tumour Biol 2016;37:3359-64.
Huang Y, Dong W, Li J, Zhang H, Shan Z, Teng W. Differential expression patterns and clinical significance of estrogen receptor-α and β in papillary thyroid carcinoma. BMC Cancer 2014;14:383.
Hao Y, Jin C, Wang J. Expression and clinical significance of Muc1, p63 protein in a diffuse sclerosing variant of papillary thyroid carcinoma and conventional papillary thyroid carcinoma. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2013;27:457-61.
Yip L, Nikiforova MN, Yoo JY, McCoy KL, Stang MT, Armstrong MJ, et al. Tumor genotype determines the phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients. Ann Surg 2015;262:519-25.
Xue G, Huang J, Zhang H, Zhang W, Wu J, Shang X. The expression and significance of trefoil factor 3 and SDF-1/CXCR4 biological axis in papillary thyroid carcinoma. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2014;28:108-12.
Marecko I, Cvejic D, Selemetjev S, Paskas S, Tatic S, Paunovic I, et al. Enhanced activation of matrix metalloproteinase-9 correlates with the degree of papillary thyroid carcinoma infiltration. Croat Med J 2014;55:128-37.
Wang JR, Li XH, Gao XJ, An SC, Liu H, Liang J, et al. Expression of MMP-13 is associated with invasion and metastasis of papillary thyroid carcinoma. Eur Rev Med Pharmacol Sci 2013;17:427-35.
Rossi ED, Martini M, Bizzarro T, Capodimonti S, Cenci T, Lombardi CP, et al. (2015). Uncommon BRAF mutations in the follicular variant of papillary thyroid carcinoma: new insights. Cancer Cytopathol 2013;123:593-602.
Cheng Y, Meng Y, Liang Z, Yang C, Luo Y, Cui Q. Expression of EpCAM and E-cadherin in papillary thyroid carcinoma and its clinicopathologic significance. Zhonghua Bing Li Xue Za Zhi 2015;44:189-94.
Prescott JD, Zeiger MA. The RET oncogene in papillary thyroid carcinoma. Cancer 2015;121:2137-46.
Published
How to Cite
Issue
Section
